Spondyloarthritis & psoriatic arthritis
Complement Proteins L-Ficolin and M-Ficolin Are Increased in Patients With Axial Spondyloarthritis and Decrease After Tumor Necrosis Factor Inhibitor Treatment
Authors' conclusion
L-ficolin and M-ficolin levels are elevated in newly diagnosed patients with axSpA compared with clinically relevant controls. Both L-ficolin and M-ficolin levels decrease significantly after initiating ADA therapy.
Study context
- Population
- Patients with low back pain (cross-sectional cohort) and patients with axial spondyloarthritis (axSpA) initiating adalimumab (trial cohort)2 cohorts
- Participants
- 23 / 55 / 64 / 49
- Exposure
- axSpA vs unspecific LBP (uLBP) with ≥1 SpA features vs uLBP without SpA features; lectin pathway protein levels before vs after ADA
- axSpAn = 23
- uLBP with SpA featuresn = 55reference
- uLBP without SpA featuresn = 64reference
- axSpA initiating ADAn = 49
- Outcome
- Plasma lectin pathway protein levels (MBL, collectin liver 1, H-ficolin, L-ficolin, M-ficolin, MASP-1, MASP-2, MASP-3, MAp19, MAp44)
Methodological detailscross-sectional cohort, longitudinal cohort from a randomised double-blind placebo-controlled trial
- Cross-sectional cohort
- Longitudinal cohort from a randomised double-blind placebo-controlled trial
Main finding
As reported in the abstract
- L-ficolin and M-ficolin significantly increased in newly diagnosed axSpA vs clinically relevant uLBP controls
- all P < 0.05
Observational data: associations, not effects.
Further findings
- Both L-ficolin and M-ficolin decreased significantly after ADA therapy
- P < 0.05
Original publication
Complement Proteins L-Ficolin and M-Ficolin Are Increased in Patients With Axial Spondyloarthritis and Decrease After Tumor Necrosis Factor Inhibitor Treatment. J Rheumatol. Published 15 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →